Aicuris Announces Pritelivir Met Primary Endpoint in Immunocompromised Patients with Refractory Herpes Simplex Virus in Phase 3 Pivotal Trial

Pritelivir demonstrated clinically meaningful and highly statistically significant superiority (p=0.0047) in lesion healing up to 28 days of treatment, compared with standard-of-care (SoC) treatments in refractory Herpes Simplex Virus (HSV) infected immunocompromised patientsPritelivir was well tolerated and had a favorable safety profile over the treatment durationFull results will be presented at an upcoming medical conference and will form the basis for regulatory filings with the FDA and globally

Wuppertal, Germany, October 16, 2025 - Aicuris Anti-infective Cures AG today announced that the registrational Phase 3 trial (PRIOH-1, NCT03073967) with its lead candidate pritelivir, a first-in-class helicase primase inhibitor for HSV, has met its primary endpoint of superiority (p=0.0047) in lesion healing in patients receiving treatment up to 28 days. Statistical superiority in lesion healing further increased in patients receiving up to 42 days of treatment (p